Back to results
US 2024/0180982 A1Published application
Modified adenovirus
OwnerAlan PARKER, James DAVIES +1inventors
InventorsAlan PARKER, James DAVIES, Emily BATES
Life of this patent
Estimating the term…
Abstract
The invention concerns a modified low seroprevalence adenovirus: a pharmaceutical composition comprising same; and a method of treating cancer using same.
Claims22
A modified D species human adenovirus of serotype 10, HAdV-D10, comprising:
- a binding epitope with selective affinity for αvβ6 integrin, comprising or consisting of a 20 amino acid peptide, NAVPNLRGDLQVLAQKVART (SEQ ID NO:
- 1), termed A20 and native to foot and mouth disease virus (termed HAdV-D10.A20);
- and any one or more of the following features:
- a) an IC50 for the coxsackievirus and adenovirus receptor (CAR) greater than 0.001 μg/105 cells;
- and/or
- b) a lack of binding to human coagulation factor X (FX);
- and/or
- c) transduction ability in the presence of serum neutralising anti-HAdV-C antibodies.
5 more elements
Dependencies are inferred from the claim text.